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Neural activity regulates dendrite and synapse
development, but the underlying molecular
mechanisms are unclear. Ca2+/calmodulin-
dependent protein kinase II (CaMKII) is an im-
portant sensor of synaptic activity, and the
scaffold protein liprina1 is involved in pre- and
postsynaptic maturation. Here we show that
synaptic activity can suppress liprina1 protein
level by two pathways: CaMKII-mediated deg-
radation and the ubiquitin-proteasome system.
In hippocampal neurons, liprina1 mutants that
are immune to CaMKII degradation impair den-
drite arborization, reduce spine and synapse
number, and inhibit dendritic targeting of re-
ceptor tyrosine phosphatase LAR, which is im-
portant for dendrite development. Thus, regu-
lated degradation of liprina1 is important for
proper LAR receptor distribution, and could
provide a mechanism for localized control of
dendrite and synapse morphogenesis by activ-
ity and CaMKII.
INTRODUCTION
Activity-dependent calcium entry into neurons induces
a variety of changes, ranging from transient posttransla-
tional modifications of synaptic proteins to altered gene
expression. At excitatory synapses, Ca2+ influx through
voltage-gated Ca2+ channels and ionotropic glutamate re-
ceptors (particularly NMDA receptors) triggers biochemi-
cal cascades that regulate synaptic function (Kennedy
et al., 2005; Sheng and Kim, 2002). Calcium signaling
pathways also control neuronal differentiation, axon path
finding, and dendrite morphogenesis (Wong and Ghosh,
2002).DeveAmajor player in all these processes is calcium/calmod-
ulin-dependent protein kinase II (CaMKII), a calcium-acti-
vated serine/threonine kinase that is abundant in neurons,
especially at postsynaptic sites (Lisman et al., 2002;Wong
and Ghosh, 2002). The CaMKII holoenzyme, consisting of
approximately 12 a and/or b subunits, is the most abun-
dant constituent of the postsynaptic density (PSD) (Cheng
et al., 2006). In mature hippocampal neurons, both
CaMKIIa and CaMKIIb are present at postsynaptic sites
but seem toplay different roles (Fink et al., 2003; Thiagarajan
et al., 2002). Ca2+/calmodulin binding to CaMKII subunits
stimulates intersubunit Thr286 autophosphorylation (re-
sulting in an activated kinase) and leads to phosphoryla-
tion of many substrates (Lisman et al., 2002).
Several CaMKII substrates, such as the NR2B subunit
of NMDA receptors and the Drosophila homolog of mam-
malian CASK, Camguk, interact directly with CaMKII (Col-
bran and Brown, 2004; Griffith, 2004). These interactions
differ in their dependence on Ca2+/calmodulin binding
and autophosphorylation and require different domains
of the kinase; some even appear to be specific for either
CaMKIIa (densin-180) or CaMKIIb (F-actin) (Colbran and
Brown, 2004). The variety of CaMKII interactions with neu-
ronal proteins could target CaMKII to specific subcellular
domains and modulate CaMKII activity during synapse
formation (Fink et al., 2003), synaptic plasticity (Thiagara-
jan et al., 2002), axonal arborization, and dendrite mor-
phogenesis (Gaudilliere et al., 2004; Wu and Cline,
1998). By functioning as a local calcium sensor, CaMKII
exerts a critical influence on the architecture of the devel-
oping and plastic brain.
The liprina family of proteins (liprina1, -a2, -a3, -a4) was
originally identified by its interaction with the leukocyte
common antigen-related (LAR) family of receptor protein
tyrosine phosphatases (LAR-RPTPs) (Pulido et al., 1995).
Liprina proteins consist of an N-terminal coiled-coil region
that mediates homo- and heteromultimerization, followed
by three SAM domains making up the liprin homology
region (LH) that binds to the D2 (inactive phosphatase)lopmental Cell 12, 587–602, April 2007 ª2007 Elsevier Inc. 587
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CaMKII-Dependent Liprina1 DegradationFigure 1. Regulation of Liprina Levels by CaMKII and Proteasome in Hippocampal Neurons
(A) Representative images of rat hippocampal neurons (DIV13) double-labeled with rabbit anti-liprina antibody (green) and mouse anti-CaMKIIa an-
tibody (red). Only the merge is shown in color. Dendritic segments (lower panels) are enlarged to show colocalization of liprina and CaMKIIa in spines.
One single spine is enlarged (inset).
(B) Dendrites of hippocampal neurons triple-labeled with rabbit anti-liprina antibody (green), guinea pig anti-PSD-95 antibody (red), and mouse anti-
bassoon (blue). High-magnification panels (bottom) show three examples of synaptic clusters triple-stained for liprina (green), PSD-95 (red), and
bassoon (blue).
(C) Dendrites of hippocampal neurons at DIV17 treated with control vehicle (Mock), KN93 (10 mM), TTX (2 mM), or bicuculline (BICUC, 40 mM) for 24 hr
and double-stained for liprina (green) and PSD-95 (red), as indicated.
(D) Quantification of number of liprina and PSD-95 clusters per 10 mmdendrite, normalized to control. Hippocampal neurons at DIV17 were treated for
24 hr with control vehicle () or KN92 or KN93 (+) in combination with TTX and bicuculline (BICUC), as indicated. Histograms indicate mean ± SEM.588 Developmental Cell 12, 587–602, April 2007 ª2007 Elsevier Inc.
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CaMKII-Dependent Liprina1 Degradationdomain of LAR-RPTPs (Serra-Pages et al., 1998). In cul-
tured cell lines, liprinas regulate LAR localization and clus-
tering (Serra-Pages et al., 1995, 1998). In Drosophila, both
liprina and LAR are required for photoreceptor axon tar-
geting in the visual system (Choe et al., 2006; Hofmeyer
et al., 2006) and normal synaptic morphology at the larval
neuromuscular junction (Kaufmann et al., 2002). Mutants
in the Caenorhabditis elegans liprina homolog syd-2 dis-
play an abnormally diffuse distribution of presynaptic
markers, lengthening of active zones, and impaired syn-
aptic transmission (Zhen and Jin, 1999).
In mammals, liprina proteins bind to several proteins
present at presynaptic sites (Schoch and Gundelfinger,
2006). Together with data showing altered synaptic vesi-
cle movement in Drosophila liprina mutants (Miller et al.,
2005), it is believed that in axons, liprina has a role both
in synaptic vesicle trafficking and active zone organiza-
tion. However, liprina is also localized in dendrites and
postsynaptic sites, suggesting additional roles (Ko et al.,
2003; Shin et al., 2003; Wyszynski et al., 2002). A postsyn-
aptic function for liprina has been described in hippocam-
pal neurons, where liprina binds to glutamate receptor
interacting protein (GRIP) and regulates synaptic targeting
of AMPA receptors (Wyszynski et al., 2002). In addition,
liprina associates with cadherin-b-catenin and, in con-
junction with LAR-RPTPs, regulates its trafficking; in this
way, liprina is implicated in the development and/or main-
tenance of dendritic spines and excitatory synapses
(Dunah et al., 2005).
Here we describe a novel activity-dependent regulation
of liprina by CaMKII, in which liprina1 is degraded in
response to CaMKII phosphorylation. Liprina1 levels in
hippocampal neurons are additionally regulated by the
ubiquitin-proteasome system (UPS) via the E3 ubiquitin
ligase anaphase promoting complex (APC). Expression of
liprina1mutants insensitive to CaMKII degradation specif-
ically inhibits the dendritic targeting of LAR receptors and
leads to reduced dendrite arborization and synapse num-
ber. These findings provide a molecular basis for activity-
dependent regulation of dendrite and synapse develop-
ment by CaMKII, liprina1, and LAR-RPTPs.
RESULTS
Downregulation of Liprina in Hippocampal Neurons
by CaMKII and Proteasome-Mediated Degradation
In screening for synaptic proteins whose abundance is
regulated by synaptic activity, we discovered that liprina
levels fluctuate greatly in response to altered activity in
cultured neurons. Liprina proteins are present at both pre-
synaptic and postsynaptic sites in the brain (Dunah et al.,Develo2005; Wyszynski et al., 2002). In cultured hippocampal
neurons (17 days in vitro; DIV17) fixed with ice-cold meth-
anol, immunostaining with antibody made against liprina1
shows a punctate pattern as previously described (Ko
et al., 2003; Shin et al., 2003; Wyszynski et al., 2002), co-
localizing with CaMKIIa in dendritic spines (Figure 1A). Li-
prina puncta also showed extensive overlap with PSD-95,
a postsynaptic density protein, and with bassoon, a pre-
synaptic active zone protein (Figure 1B), indicating the
presence of liprina at synapses. The intensity of liprina
staining was generally weaker and more variable than
the staining of these synaptic markers, such that some
synapses had robust liprina staining while other synapses
showed undetectable signal (Figures 1A and 1B). Quanti-
fication revealed that 90% of liprina puncta overlapped
with PSD-95 and bassoon clusters, but only 30% of
the PSD-95 and bassoon coclusters contained liprina
staining (Figure 1B; see Figure S1C in the Supplemental
Data available with this article online).
Suppressing activity with tetrodotoxin (TTX, 2 mM, 24 hr)
strongly increased liprina expression, whereas increasing
synaptic activity with the GABAA receptor antagonist
bicuculline (40 mM, 24 hr) reduced liprina expression in
cultured hippocampal neurons (DIV17) (Figure 1C). The
density of liprina clusters doubled in TTX-treated cells,
associated with increased immunofluorescence intensity
of the clusters (Figures 1C and 1D; Figures S1A and
S1C). Bicuculline profoundly reduced liprina puncta den-
sity and brightness of staining. PSD-95 immunostaining
showed similar bidirectional trends with altered activity,
but the magnitude of fluctuation was much lower than
that of liprina (Figures 1C and 1D; Figures S1A and
S1C).Western blotting confirmed that liprina protein levels
fell with increased activity (bicuculline) and rose with inac-
tivity (TTX) (Figure 1E).
We tested whether CaMKII might play a role in the activ-
ity-dependent loss of liprina, because this protein kinase
is activated by synaptic excitation. Bath application of
KN93, an inhibitor of CaMKII, strongly enhanced liprina
protein levels (Figure 1E) and increased the brightness
and density of liprina clusters (Figures 1C and 1D).
KN92, an inactive analog of KN93, had no effect on liprina
levels by Western blot or by immunocytochemistry (Fig-
ures 1D and 1E). Again, PSD-95 showed a similar trend
with KN93, but the degree of increase was much smaller
than that of liprina (Figures 1C and 1D). Thus, KN93
mimics the effect of TTX on liprina expression. More im-
portantly, KN93 prevented the effect of bicuculline and
‘‘rescued’’ liprina back to control levels (Figures 1D and
1E); however, liprina expression in neurons treated with
both KN93 and bicuculline did not reach the high level(E) Hippocampal cultures (DIV17) were treated for 24 hr with control vehicle () or KN92 or KN93 (+) in combination with TTX or BICUC, as indicated.
Total lysates were immunoblotted for liprina and a-tubulin as a loading control.
(F) Dendrites of hippocampal neurons at DIV17 treated with control vehicle (Mock), lactacystin (5 mM),MG132 (20 mM), or a combination of BICUC and
MG132 for 24 hr and double-stained for liprina (green) and PSD-95 (red).
(G) Number of liprina and PSD-95 clusters per 10 mm dendrite (mean ± SEM). Hippocampal neurons at DIV17 were treated for 24 hr with control ve-
hicle () or MG132 (+), with or without BICUC, as indicated. The number of clusters is normalized to unstimulated conditions.
(H) Hippocampal cultures (DIV17) were treated for 24 hr with control vehicle () or MG132 (+), with or without BICUC, as indicated. Total lysates were
immunoblotted for liprina and a-tubulin as a loading control. *p < 0.05, **p < 0.005, ***p < 0.0005.pmental Cell 12, 587–602, April 2007 ª2007 Elsevier Inc. 589
Developmental Cell
CaMKII-Dependent Liprina1 Degradationseen with KN93 alone (Figures 1D and 1E). These data
indicate that CaMKII plays an important role in activity-
dependent loss of liprina, but suggest that additional
independent mechanisms might be involved.
Because the UPS plays an important role in synaptic
protein turnover (Ehlers, 2003), we tested whether protea-
some inhibitors affected liprina expression in hippocam-
pal neurons. MG132 (20 mM, 24 hr) or lactacystin (5 mM,
24 hr) caused a robust increase in liprina protein levels
and in liprina cluster density (Figures 1F–1H; Figures
S1B and S1C). MG132 also blocked the reduction of
liprina by bicuculline (Figures 1F and 1G; Figures S1B
and S1C); however, liprina level or cluster number did
not reach the high values seen with MG132 alone (Figures
1F–1H). These data indicate that proteasome-mediated
degradation keeps the ‘‘basal’’ level of liprina low and con-
tributes substantially to activity-induced loss of liprina;
however, additional mechanisms seem to be involved,
as noted above for CaMKII. Another possibility is that
CaMKII- and proteasome-mediated downregulation of
liprina1 activity only partially depend on synaptic activity,
as induced by bicuculline. Together, our results suggest
that downregulation of liprina in hippocampal neurons
is mediated by CaMKII activity as well as proteasome
degradation.
RNAi Knockdown of APC Increases Liprina
In Drosophila neurons, liprina may be regulated by APC,
which acts as an E3 ubiquitin ligase (van Roessel et al.,
2004). APC consists of >11 core subunits, including cata-
lytic subunits APC2 and APC11, and is activated by regu-
latory subunits such as Cdh1 (Konishi et al., 2004). We
tested whether APC might regulate liprina1 in mammalian
neurons by using small hairpin RNA (shRNA) expressed
from the pSuper vector to knock down endogenous
APC2 and Cdh1. Hippocampal neurons were transfected
at DIV13 for 4 days with two independent APC2-shRNA
(APC2-shRNA1 or APC2-shRNA2) or Cdh1-shRNA con-
structs, together with b-galactosidase (b-gal) to mark
transfected neurons. To better preserve the b-gal staining,
these cultures were fixed with formaldehyde, which re-
sults in a more diffuse staining of liprina in dendrites in ad-
dition to the punctate synaptic pattern seen predomi-
nantly under methanol fixation conditions (Figures S2A
and S2D). In neurons transfected with APC2-shRNA or
Cdh1-shRNA constructs (Konishi et al., 2004), the inten-
sity of liprina immunostaining in dendrites was drastically
increased (100%–150% increase compared to control
neurons) (Figures S2A and S2B). The intensity of PSD-
95, revealed by double-staining, was unchanged in the
same neuron (Figure S2C). Together with the MG132
and lactacystin results, these findings indicate that the
UPS, particularly that mediated by APC, downregulates
expression of liprina in hippocampal neurons.
CaMKIIa/b Knockdown by RNAi Increases
Liprina in Hippocampal Neurons
To test which CaMKII isoform regulates liprina levels in
hippocampal neurons, we knocked down expression of590 Developmental Cell 12, 587–602, April 2007 ª2007 Elsevieendogenous CaMKIIa or CaMKIIb by transfection of
shRNA-expressing constructs. When tested in COS-7
cells, the CaMKIIa-shRNA construct specifically inhibited
protein expression of CaMKIIa, and CaMKIIb-shRNA spe-
cifically suppressed CaMKIIb (Figure S3E). These RNAi
constructs were cotransfected in hippocampal neurons
(DIV13) with green fluorescent protein (GFP) to visualize
morphology. Cells transfected with CaMKIIa-shRNA
showed 70% reduction in immunostaining for CaMKIIa
in dendrites and cell body, with no change in CaMKIIb
staining intensity (Figures S3A–S3D). CaMKIIb-shRNA-
transfected neurons showed diminished staining for both
CaMKIIb (80% reduction) and CaMKIIa (60% reduc-
tion) (Figures S3A–S3D). Because CaMKIIb-shRNA did
not affect CaMKIIa expression in COS-7 cells, we believe
that the loss of neuronal CaMKIIa induced by CaMKIIb-
shRNA is likely a secondary consequence of CaMKIIb
knockdown than due to nonspecificity of CaMKIIb-shRNA
(for instance, CaMKIIb might be required for formation of
stable CaMKIIa/b hetero-oligomeric holoenzymes).
We measured liprina by immunostaining in hippocam-
pal neurons transfected at DIV13 with CaMKIIa-shRNA,
CaMKIIb-shRNA, or both. b-gal was cotransfected to
mark and outline the transfected cell. These cultures
were fixedwith formaldehyde. Four days after transfection
of CaMKII-shRNA (DIV13+4), the integrated intensity per
area (diffuse plus punctate staining) of liprina immunos-
taining in the dendrite shaft was increased compared to
control (30% increase for CaMKIIa-shRNA, 50% in-
crease for CaMKIIb-shRNA or CaMKIIa- + CaMKIIb-
shRNA) (Figures S2D and S2E). The intensity of PSD-95
staining was unchanged (data not shown). These RNAi
data extend the KN93 pharmacological results, confirming
that CaMKII inhibits liprina protein expression in hippo-
campal neurons. At least the CaMKIIa isoform is involved;
however, because CaMKIIb-shRNA reduces expression
of both CaMKIIa and CaMKIIb, we cannot be certain
whether CaMKIIb directly regulates liprina levels.
Active CaMKII Decreases Liprina1 Protein Level
in COS Cells
To investigate the mechanism by which liprina1 expres-
sion is suppressed by CaMKII, we first turned to heterolo-
gous cells. In COS-7 cells, exogenous myc-tagged
liprina1was expressed as a band of160 kDa (Figure 2A).
Remarkably, when constitutively active CaMKIIa (T286D)
was cotransfected, myc-liprina1 levels became virtually
undetectable (Figure 2A). Cotransfection of wild-type
CaMKIIa(WT) or kinase-dead CaMKIIa(K42R) mutant did
not affect liprina1 protein levels (Figure 2A). A similar de-
gree of suppression by cotransfected CaMKIIa(T286D)
was seen for untagged liprina1, liprina1 tagged with GFP
or HA, and liprina1 expressed from different promoters
(CMV, SV40, chicken b-actin), with or without the 30 and
50 untranslated regions of liprina1 (data not shown). These
results argue that CaMKII is not acting on the transcription
or mRNA stability of liprina1.
We also analyzed the effect of CaMKII on liprina1 by an
immunocytochemical assay. Liprina1 cotransfected intor Inc.
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CaMKII-Dependent Liprina1 DegradationFigure 2. Induction of Active CaMKIIa Suppresses Liprina1
Protein Levels
(A) COS-7 cells were double-transfected for 2 days with myc-liprina1
plus empty vector control, wild-type (WT) CaMKIIa, constitutively ac-
tive CaMKIIa(T286D), or kinase-dead CaMKIIa(K42R), as indicated.
Whole-cell lysates from transfected COS-7 cells were immunoblotted
for liprina1 and CaMKII to detect the transfected constructs, and for
endogenous cortactin as a loading control.
(B) Number of liprina1-immunopositive cells (mean ± SEM; normalized
to control) in COS-7 cultures transfected withGFP-liprina1 andCaMKII
constructs as in (C).
(C) Representative images of COS-7 cells cotransfected with GFP-
liprina1 (green) plus control vector, CaMKIIa(WT), CaMKIIa(T286D),
or CaMKIIa(K42R) (red), as indicated. The merge is shown in color at
right. The scale bar represents 100 mm. *p < 0.05, **p < 0.005, ***p <
0.0005.DeveloCOS-7 cells with empty vector control showed on average
94 liprina1-immunoreactive cells per 1.7 mm2 in a 50%–
70% confluent cell layer (Figures 2B and 2C). When
liprina1 was cotransfected with constitutively active
CaMKIIa(T286D), however, only very few cells (6 per
1.7 mm2) expressed liprina1 by immunostaining (Figures 2B
and 2C). Cotransfection with wild-type (WT) or kinase-
dead (K42R) CaMKIIa did not reduce the number of
liprina1-immunoreactive cells (Figures 2B and 2C).
To confirm that the loss of liprina1 protein is due to the
expression of CaMKIIa protein, we used a doxycycline
(DOX)-inducible expression system (TETon) and followed
over time the level of liprina1protein following the induction
of activeCaMKIIa. COS-7 cells were triply transfectedwith
GFP-liprina1, CaMKIIa(T286D) under the control of a tetra-
cycline-responsive element (pTRE-CaMKIIa[T286D]), and
a tetracycline transcriptional activator (rtTA) expression
construct. At time 0 (no DOX added), liprina1 protein was
robustly detected by immunoblot in the absence of
CaMKIIa signal (Figure 2D). From 4 to 12 hr after adding
DOX, liprina1 expressiondeclined steadily, inversely corre-
latedwithaprogressively risingCaMKIIa (Figure2D).At12hr
after DOX addition, liprina1 was almost undetectable. No
effect on liprina1 protein expression was seen 12 hr after
induction of CaMKIIa(K42R) or CaMKIIa(WT) using the
same TETon system (Figure 2D). Similar results were ob-
tainedwith theseconstructsusingan immunocytochemical
assay (Figures S4A–S4C). Induction of CaMKIIa(T286D),
but not CaMKIIa(K42R) or CaMKIIa(WT), caused a dra-
matic reduction in the number of liprina1-positive cells
over time (Figures S4A–S4C; data not shown). These
data provide compelling evidence that active CaMKIIa
suppresses liprina1 protein levels, with a time course sug-
gesting active degradation of liprina1 stimulated by
CaMKIIa.
In COS-7 cells triply transfected with liprina1, PSD-95,
and CaMKIIa, PSD-95 protein level was unaffected by
CaMKIIa(T286D), even while liprina1 disappeared
(Figure S4D). Immunocytochemistry analysis showed sim-
ilar results: the percentage of PSD-95-immunoreactive
COS cells was unaltered by cotransfection with
CaMKIIa(T286D) (Figure S4E). CaMKIIa(T286D) also had
no effect on GRIP1 (a multi-PDZ protein that binds to
liprina1 andAMPA receptors), cortactin, liprina2, or liprinb1
(proteins closely related to liprina1) (Figures S4F andS4H).
Thus, the effect of CaMKIIa(T286D) appears relatively
specific for liprina1.
Liprina1protein expression inCOScellswas also strongly
inhibited by cotransfection of active CaMKIIb(T286D), but
not by wild-type or inactive CaMKIIb(K43R) (Figure S4G).
Polo-like kinase-2 (Plk-2, also known as serum-inducible
kinase; SNK) did not affect liprina1 levels in COS cells
(D) COS-7 cells were cotransfected with myc-liprina1, pTRE-CaMKIIa
(WT, T286D, or K42R), and rtTA expression construct. Two days after
transfection, cells were treated with doxycycline (DOX) for various
times as indicated (0–12 hr), and were immunoblotted for liprina1
and CaMKII to detect the transfected constructs and for endogenous
cortactin as a loading control.pmental Cell 12, 587–602, April 2007 ª2007 Elsevier Inc. 591
Developmental Cell
CaMKII-Dependent Liprina1 DegradationFigure 3. C Terminus and PESTMotif but Not Proteasome Are Required for CaMKII-Mediated Liprina1 Degradation in COS-7 Cells
(A) Diagram of liprina1 mutant constructs (GFP or HA tag was placed at N terminus).
(B) Number of cells immunopositive for indicated liprina1 mutant constructs (mean ± SEM; normalized to control vector; not shown) when cotrans-
fected with CaMKIIa(T286D). *p < 0.05, **p < 0.005, ***p < 0.0005.
(C) Representative images of COS-7 cells cotransfected with CaMKIIa(T286D) (red) and GFP-liprina1 mutant constructs (green), as indicated. Color
merge is shown at right. The scale bar represents 100 mm.
(D) COS-7 cells cotransfected with indicated GFP-liprina1 mutant constructs plus control vector, CaMKIIa(T286D), or CaMKIIa(K42R), and immuno-
blotted for the transfected liprina1 construct using HA or GFP antibodies.592 Developmental Cell 12, 587–602, April 2007 ª2007 Elsevier Inc.
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CaMKII-Dependent Liprina1 Degradation(data not shown), even though it strongly suppressed
expression of SPAR, a Rap guanosine triphosphatase acti-
vating protein (Pak and Sheng, 2003). Thus, both CaMKIIa
and CaMKIIb can specifically suppress liprina1 expres-
sion in heterologous cells, consistent with RNAi results
obtained in neurons (see Figure S2). The data are most
simply explained by active CaMKII stimulating the degra-
dation of liprina1.
C Terminus and PEST Motif Are Essential
for CaMKII-Dependent Liprina1 Degradation
As a first step toward the molecular mechanism behind
this effect, we investigated the domains of liprina1 re-
quired for CaMKII-mediated suppression (Figure 3A).
GFP-tagged wild-type and deletion mutants of liprina1
were cotransfectedwithCaMKIIa(T286D), CaMKIIa(K42R),
or empty vector in COS-7 cells. Expression of liprina1
constructs was quantified by immunocytochemistry and
western blotting assays (Figures 3B–3D). The C-terminal
region of liprina1 contains four potential CaMKII phos-
phorylation sites (RXXS/T) which are conserved in human,
rat, mouse, and chicken liprina1 proteins. The liprina1
splice variant lacking the last 18 amino acids (liprina1a)
(Wyszynski et al., 2002), which deletes two of the putative
phosphorylation sites, and a C-terminal deletion mutant
lacking the last 88 residues (liprina1DC [1–1112]), which
is missing all four phosphorylation sites, were still effi-
ciently suppressed by CaMKIIa(T286D) and unaffected
by CaMKIIa(K42R) (Figure 3D).
Amutantwith a largerC-terminal truncation, liprina1DCM
(containing residues 1–712), was not degraded by
CaMKIIa(T286D), implying that the C-terminal half of
liprina1 contains determinants for CaMKII-induced degra-
dation (Figures 3B–3D). In this region there is a PEST (pro-
line-, glutamate-, serine-, threonine-rich) sequence (amino
acids 771–795), which is conserved among mammalian
liprina1 proteins, and which has a PEST score of +8.83
based on the PEST-FIND program (Rechsteiner and
Rogers, 1996). A PEST score of more than 5 denotes
a very strong proteolytic degradation signal. Deleting the
PEST sequence (liprina1DPEST) resulted in somewhat re-
duced susceptibility of liprina1 to CaMKII suppression,
compared with wild-type or DN (Figures 3B–3D). Combin-
ing the PEST deletion with the C-terminal deletion left a
liprina1mutant (liprina1DPESTDC) that was completely in-
sensitive to suppression by CaMKIIa(T286D) (Figures 3B–
3D). We also mutated the serine residues of the putative
C-terminal CaMKIIa phosphorylation sites to alanine
(S1139A, S1168A, S1194A, S1201A) in a DPEST back-
ground, giving rise to liprina1DPEST/S-A. The liprina1D-
PEST/S-A mutant also was insensitive to CaMKIIa(T286D)Develo(Figures 3B and 3D). Thus, both the central PEST se-
quence and the C-terminal putative CaMKII phosphoryla-
tion sites are important for liprina1 degradation by active
CaMKII.
Proteasome Is Not Involved in CaMKIIa-Dependent
Liprina1 Degradation in COS-7 Cells
The PEST motif is known to promote rapid protein turn-
over; however, the pathways responsible for degrading
PEST proteins are not always clear. Several PEST proteins
have been reported to be degraded by calpain or protea-
some, but degradation of other PEST-containing proteins
seems independent of these mechanisms (Rechsteiner
and Rogers, 1996). Two distinct proteasome inhibitors,
MG132 and lactacystin, increased the basal level of both
liprina1 and liprina1DPESTDC expressed in COS-7 cells
(Figure 3E; data not shown), implying that the proteasome
is involved in downregulating basal liprina1 levels. In con-
trast, expression of cotransfected PSD-95was unaffected
(Figure 3E). Importantly, however, 4, 8, and 12 hr MG132
treatment did not prevent the loss of liprina1 induced by
cotransfection of CaMKIIa(T286D) (Figures 3F and 3G;
data not shown), indicating that proteasome function is
not required for elimination of liprina1 by active CaMKII.
In addition, liprina1 degradation by active CaMKII was
not blocked by calpain inhibitors (ALLN, ALLM) or inhibi-
tors of lysosomal degradation (chloroquine, leupeptin,
ammonium sulfate) (data not shown). Overall, these data
indicate that although it contributes to basal lowering of
liprina1, proteasomal activity is not essential for CaMKII-
mediated degradation of liprina1 in heterologous cells.
Interaction of CaMKII and Liprina1
In Vitro and In Vivo
Ourmutational analysis suggests that liprina1 is a target of
CaMKII phosphorylation; therefore, we tested whether
liprina1 and CaMKII interact biochemically. From cotrans-
fected COS-7 cells, liprina1 was readily coimmunopreci-
pitated with CaMKIIa wild-type and K42R (Figures 4A
and 4B). For this experiment, we could not use the
CaMKIIa(T286D) construct, as active CaMKII causes a
drastic reduction in the amount of liprina1. Nonimmune
rabbit IgG immunoprecipitated neither liprina1 nor CaMKII,
and liprina2, cortactin, and PSD-95 could not be copreci-
pitated with wild-type CaMKIIa (Figures 4A–4C), indicating
a specific interaction between liprina1 and CaMKIIa. The
association with CaMKIIa was lost in the liprina1 mutant
DCM but retained in DN, indicating that CaMKII interacts
with theC-terminal half of liprina1 (Figure 4D). Interestingly,
the mutant DPESTDC, although insensitive to CaMKII-
mediated degradation, could be coimmunoprecipitated(E) COS-7 cells cotransfected with myc-PSD-95 plus GFP-liprina1 or GFP-liprina1DPESTDC were treated (+) or not treated () with 5 mg/ml MG132
for 4 hr and immunoblotted for myc and GFP. Endogenous a-tubulin was used as a loading control.
(F) COS-7 cells transfected with GFP-liprina1 or GFP-liprina1DPESTDC plus control vector () or CaMKIIa(T286D) (+) were treated (+) or not treated
() with 5 mg/ml MG132 for 4 hr as indicated, and immunoblotted for GFP or CaMKIIa. Endogenous b-catenin was used as a positive control for
MG132 treatment.
(G) Representative images of COS-7 cells cotransfected with GFP-liprina1 (green) and control vector or CaMKIIa(T286D) (red), and treated with
5 mg/ml MG132 for 4 hr.pmental Cell 12, 587–602, April 2007 ª2007 Elsevier Inc. 593
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are responsible for interaction with CaMKII (see Figure 3A
for diagram). Notable in this respect is the recent discovery
that theCaMKII-like domain of scaffold proteinCASK inter-
acts with the SAM region of liprina1 (Olsen et al., 2005).
To test for an in vivo interaction, we performed coimmu-
noprecipitations from deoxycholate extracts of rat cere-
bral cortex. Consistent with earlier studies (Dunah et al.,
2005; Wyszynski et al., 2002), GRIP and GluR2/3 were ro-
bustly coprecipitated with the liprina antibody (Figure 4E).
Liprina antibodies also precipitated significant amounts of
CaMKIIa. In the inverse reaction, CaMKIIa antibodies
brought down a small amount of liprina and GRIP in addi-
tion to precipitating CaMKIIa, but no detectable GluR2/3
(Figure 4E). As a negative control, PSD-95 and cortactin
were not coprecipitated by liprina or CaMKIIa antibodies
and none of the analyzed proteins was pelleted by nonim-
mune rabbit IgG (Figure 4E). These biochemical data sug-
Figure 4. CaMKII Interaction with Liprina1 In Vitro and In Vivo
(A and B) COS-7 cells cotransfected with wild-type (WT) GFP-CaMKIIa
and myc-liprina1 (A), or GFP-CaMKIIa(K42R) and myc-liprina1 (B),
were immunoprecipitated with nonimmune rabbit IgG or CaMKII anti-
bodies. Each immunoprecipitation reaction is shown in three lanes: I,
input to IP reaction; S, supernatant remaining after IP; P, precipitated
pellet. The I, S, and P samples were immunoblotted for the indicated
proteins.
(C and D) COS-7 cells cotransfected with GFP-CaMKIIa(WT) and indi-
cated proteins (C) or liprina1 mutant constructs (D) were immunopre-
cipitated and immunoblotted as in (A) and (B).
(E) Coimmunoprecipitation of CaMKII and liprina from rat cortex. De-
oxycholate extracts were immunoprecipitated with nonimmune rabbit
IgG or CaMKIIa or liprina antibodies, and immunoblotted for the pro-
teins indicated at right.594 Developmental Cell 12, 587–602, April 2007 ª2007 Elseviegest that a subset of CaMKIIa is present in some fraction
of the liprina protein complex in vivo as well as in vitro,
which is consistent with the colocalization of liprina and
CaMKII clusters at synaptic sites (Figures 1A and 1B).
Liprina1DPESTDC and Liprina1DPEST/S-A Inhibit
Dendrite Morphogenesis and Reduce Synapse
Density
What is the functional significance in neurons of liprina1
degradation by CaMKII? To address this question, we
transfected hippocampal neurons (DIV13) with liprina1
wild-type versus liprina1DPESTDC or liprina1DPEST/S-A
mutants that can no longer be degraded by CaMKII.
Note, however, that thesemutants are sensitive to protea-
some downregulation, insofar as their basal levels are in-
creased by MG132 (Figure 3E). Neuronal morphology
was visualized by cotransfected monomeric red fluores-
cent protein (mRFP). Four days after transfection, neurons
transfected with liprina1DPESTDC or liprina1DPEST/S-A
showed stunted dendritic arbors relative to neurons trans-
fected with liprina1 (Figure 5A; data not shown). Com-
pared with vector control, overexpression of wild-type
liprina1 had no effect on any dendrite parameter mea-
sured (total dendritic length, number of primary dendrites
or dendrite tips, and density or size of dendritic protru-
sions) (Figures 5A and 5D–5F). Total dendritic length
decreased by 30% in liprina1DPESTDC- and liprina1D-
PEST/S-A-transfected neurons (Figures 5A and 5D). Den-
drite branching was also reduced, as quantified by total
number of dendrite tips (40% decrease; Figure 5E) or
by Sholl analysis (which measures the number of den-
drites crossing circles at various radial distances from
the cell soma; Figure 5C). Liprina1DPESTDC and lipri-
na1DPEST/S-A also decreased (by 25%) the number
of primary dendrites (defined as dendrites longer than
21 mm emanating directly from the soma) (Figure 5F). Al-
though overexpression of wild-type liprina1 had no effect
on dendrite morphology, KN93 treatment of wild-type
liprina1-transfected cells mimicked the effects of overex-
pression of CaMKII-nondegradable mutants on dendrite
morphology (Figures 5A and 5C–5F). As expected, levels
of wild-type liprina1 protein were increased in cells treated
with KN93. In summary, the expression of ‘‘stable’’ liprina1
caused a decrease in the number of primary, secondary,
and higher-order dendrites and a reduction in the dendritic
arbor complexity in cultured hippocampal neurons. We
conclude that CaMKII-mediated degradation of liprina1
is essential for normal growth and maturation of the
dendritic tree.
The density of dendritic protrusions and spines (defined
as protrusions of 14 mm in length that showed a clear
‘‘head’’) at DIV17 was reduced by liprina1DPESTDC and
liprina1DPEST/S-A, but unaffected by wild-type liprina1
(Figures S5A and S5B). The mean length and width of re-
maining spines were not substantially different in neurons
overexpressing any of the liprina1 constructs (Figures
S5A, S5C, and S5D). In accord with a reduction in the
number of spines, we observed an 40% fall in the den-
sity of bassoon puncta on neurons transfected withr Inc.
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of dendrite versus liprina1DPEST/S-A: 2.74 ± 0.28 per
10 mm length of dendrite), an indication that neurons ex-
pressing CaMKII-insensitive liprina1 harbor fewer presyn-
aptic contacts. Thus, in addition to reduced dendrite
branching, CaMKII-nondegradable liprina1 mutants im-
pair the development and/or maintenance of spines and
synapses.
LAR-Liprin Interfering Constructs and LAR-shRNA
Inhibit Dendrite Morphogenesis
We investigated which domain of liprina1 is important for
dendrite morphology by overexpressing liprina1 deletion
constructs liprina1DN, liprina1SAM, and liprina1DCM
(see Figure 3A), assuming that the mutants work as dom-
inant negatives. Four days after transfection, neurons ex-
pressing liprina1DN and liprina1SAM showed shorter
dendritic arbors relative to neurons transfected with con-
trol vector or liprina1DCM (Figures 5B and 5D), similar to
liprina1DPESTDC- and liprina1DPEST/S-A-transfected
cells. Dendrite branching was also reduced, as quantified
by dendrite tips (30%decrease; Figure 5E), primary den-
drites (25% decrease; Figure 5F), and Sholl analysis
(Figure 5C). The density of dendritic protrusions and
spines at DIV17 was reduced by liprina1DN and liprina1-
SAM, but unaffected by liprina1DCM (Figures S5A–S5D).
These data argue that the SAM domain of liprina1 is im-
portant for supporting dendrite morphogenesis and nor-
mal spine number.
The LAR-RPTPs bind to the SAM domains in liprina1
(Serra-Pages et al., 1995). Therefore, we investigated the
effect on dendrite morphogenesis of overexpression of
the isolated liprina binding domain of LAR (LAR-D2, fused
to a myristoylation motif for membrane targeting), or
knockdown of LAR by LAR-shRNA (Dunah et al., 2005).
Expression of either LAR-D2 or LAR-shRNA caused
marked pruning of the dendritic arbor (Figures 5B–5F)
and loss of dendritic protrusions and spines (Figures
S5A–S5D). In summary, the expression of constructs
that disrupt the liprina1-LAR interaction or that suppress
endogenous LAR expression caused a reduction in den-
drite arborization and spine density in hippocampal neu-
rons, similar to the effects seen with neurons expressing
CaMKII-nondegradable liprina1 constructs.
Liprina1 Increases Surface Expression
and Clustering of LAR Receptors
Liprina has been suggested to regulate LAR localization
and clustering in mammalian cell lines (Serra-Pages
et al., 1995, 1998). It is difficult to study the regulation of
endogenous LAR trafficking in neurons because LAR pro-
tein is not highly expressed and our LAR antibodies work
insufficiently in immunostaining. We developed a simpli-
fied way to investigate LAR receptor trafficking, which
makes use of the CD8 glycoprotein as a reporter in protein
trafficking (Hoogenraad et al., 2005). A GFP-tagged CD8
construct containing only the extracellular and transmem-
brane domain of CD8 accumulated in the endoplasmic re-
ticulum of HeLa cells, colocalizing with calreticulin (Fig-Deveures S6A and S6B); expression on the cell surface was
weak (Figure S6C). Fusing the entire cytoplasmic domain
of LAR (LARC) to the CD8 construct allowed the chimeric
construct (CD8-LARC) to leave the endoplasmic reticulum
and accumulate in the perinuclear Golgi region (Fig-
ure S6D), where it colocalized with the trans-Golgi marker
BICD2 (Figure S6E).
In the absence of coexpressed liprina1, very little CD8-
LARC was associated with the cell surface (Figure 6E).
Cotransfectionwith liprina1, liprina1DPESTDC, or liprina1D-
PEST/S-A resulted in greatly increased expression of
CD8-LARC at the surface in a patchy pattern in almost all
cells (Figures6A, 6B, and 6F). Coexpressionof liprina1DCM,
lacking the LAR binding domain, did not change the
distribution of CD8-LARC, which remained in a Golgi
pattern (Figure 6C). Similarly, the CD8-LARCDD2 con-
struct lacking the liprin binding site was unaffected by
cotransfection of liprina1DPESTDC (Figure 6D). These
data in heterologous cells suggest that one function of
liprina1 (bothwild-typeandCaMKII-nondegradablemutants)
is to drive LAR receptors out of the Golgi and deliver them
to the cell surface.
CaMKII-Nondegradable Liprina1 Mutants Impair
Dendritic Targeting of LAR
We next investigated LAR trafficking in hippocampal neu-
rons. When overexpressed in neurons, CD8-LARC was
found, in addition to the perinuclear Golgi region (Fig-
ure S7B), in a punctate pattern in dendrites (Figure 7A,
left, inset, arrowheads) and at low levels on the cell surface
(Figure S7A). Overexpression of wild-type liprina1 has no
effect on the CD8-LARC distribution (Figure 7B). However,
cotransfection of liprina1DPESTDC and liprina1DPEST/S-
A mutants caused redistribution of CD8-LARC from Golgi
and accumulation of CD8-LARC in neuronal cell bodies
(Figures 7C–7E; Figure S7B). In these neurons, CD8-
LARC was predominantly found in a patchy pattern along
the periphery of the cell body, suggesting an increased
surface expression on the soma (Figure 7C; Figure S7B).
The ratio of cell body (soma without the Golgi)/Golgi im-
munostaining for CD8-LARC increased 2-fold in liprina1D
PESTDC- and liprina1DPEST/S-A-expressing neurons
compared to control (Figure 7E), indicating improved exit
from Golgi toward the somatic surface, similar to the find-
ings in HeLa cells. Despite the increased expression on
neuronal somata, the punctate staining of CD8-LARC in
the dendrites was greatly reduced (Figure 7C). The ratio
of dendrite/Golgi immunostaining for CD8-LARC de-
creased 2-fold in neurons expressing liprina1DPESTDC
or liprina1DPEST/S-A (Figure 7D), signifying that
CaMKII-nondegradable liprina1 mutants impair dendritic
targeting of LAR, despite improving Golgi-to-somatic sur-
face transport. The distribution of CD8-LARCDD2, lacking
the liprina binding site, was unaffected by CaMKII-nonde-
gradable liprina1 constructs (Figures 7D and 7E). In neu-
rons transfected with HA-liprina1 and treated with KN93
(10 mM, 24 hr), the ratio of cell body/Golgi intensity of
CD8-LARC immunostaining increased 2-fold and the den-
drite/Golgi ratio decreased 2-fold compared to untreatedlopmental Cell 12, 587–602, April 2007 ª2007 Elsevier Inc. 595
Developmental Cell
CaMKII-Dependent Liprina1 Degradation596 Developmental Cell 12, 587–602, April 2007 ª2007 Elsevier Inc.
Developmental Cell
CaMKII-Dependent Liprina1 Degradationliprina1-transfected cells (Figures 7D and 7E), mimicking
the effect of overexpressed CaMKII-nondegradable
liprina1 mutants. Thus, prevention of liprina1 degradation
by CaMKII, either by mutation of liprina1 or by drug inhibi-
tion of CaMKII, reduces the trafficking of CD8-LARC to
dendrites. Together, these data indicate that liprina1 deg-
radation by CaMKII is needed specifically for the dendritic
targeting of LAR, thereby promoting normal development
of dendrites and synapses.
DISCUSSION
Activity-Dependent Regulation of Liprina1 by Two
Mechanisms: CaMKII and Proteasome
Activity regulates the expression and degradation of many
neuronal proteins, including several scaffolds of the PSD
(Ehlers, 2003). One of the major cellular mechanisms con-
trolling protein turnover is the UPS (Hegde and DiAntonio,
2002; Murphey andGodenschwege, 2002). Ubiquitin-pro-
cessing enzymes play an essential role in neural develop-
ment, including synapse growth and development, growth
cone guidance, and dendritic remodeling (Kuo et al., 2005;
Murphey and Godenschwege, 2002). In most cases, the
importance of the UPS for neural development is inferred
from pharmacological inhibitor or genetic loss-of-function
studies, and the specific proteins whose level is controlled
by ubiquitination and proteasomal proteolysis are un-
known. Here we found liprina1 levels to be particularly
susceptible to activity-dependent regulation. The sup-
pression of liprina1 protein by neural activity depends at
least partially on CaMKII and proteasome function. Be-
cause inhibitors of either CaMKII or proteasome coun-
tered the effect of activity but did not elevate liprina1 to
the high levels seen with the inhibitors alone, we hypothe-
size that synaptic activity stimulates at least two pathways
for liprina1 degradation: one depending on CaMKII phos-
phorylation, and another depending on the UPS. This idea
is supported by the fact that proteasome inhibitors do not
prevent the degradation of liprina1 by CaMKII in COS
cells. In addition, the data in neurons can be explained if
CaMKII- and proteasome-mediated turnover of liprina1
depend only partially on synaptic activity. Cotreatment
of neurons with KN93 and MG132 did not significantly in-
crease liprina1 levels compared to either drug alone (data
not shown), which does not support the idea that CaMKII
and proteasomes lie in independent pathways for liprina1
degradation. Thus, our findings in heterologous cells do
not rule out that CaMKII degradation of liprina1 occursDevevia the UPS in neurons, or that crosstalk occurs between
these pathways.
Our findings indicate that CaMKII affects liprina1 levels
via protein degradation as opposed to a reduction in tran-
scription or translation. To our knowledge, this is the first
example of CaMKII signaling in which CaMKII activity
stimulates degradation of a specific protein. The degrada-
tion of liprina1 by CaMKII involves a central PEST se-
quence and C-terminal phosphorylation sites in liprina1.
At least 12 CaMKII consensus phosphorylation sites are
present in liprina1. Phosphorylation of the C-terminal tail
and CaMKII sites close to the PEST sequence may recruit
degradation factors necessary for proteolysis (Garcia-Alai
et al., 2006). Alternatively, CaMKII phosphorylation may
induce conformation changes in liprina1 which open up
additional regions involved in rapid protein degradation.
Although mutation analysis in liprina1 suggests a direct
role for CaMKII phosphorylation in liprina1 degradation,
we cannot rule out that another factor is activated by
CaMKII which subsequently causes liprina1 degradation.
A PEST motif is absent in liprina2, which is not degraded
by active CaMKII, but present in themiddle part of liprina4,
which additionally contains two CaMKII phosphorylation
sites in its C terminus. Thus, liprina4 might also be de-
graded by active CaMKII.
Given that liprina1 exists on both sides of mammalian
excitatory synapses (Dunah et al., 2005; Ko et al., 2003;
Shin et al., 2003;Wyszynski et al., 2002), does activity reg-
ulate the level of liprina at pre- or postsynaptic sites?
CaMKII is extremely abundant in the postsynaptic density
(Cheng et al., 2006; Lisman et al., 2002), but also exists in
axon terminals (Liu and Jones, 1997). Moreover, activity
results in Ca2+ elevation in both pre- and postsynaptic
compartments. Light microscopy cannot definitely distin-
guish between pre- and postsynaptic accumulation of
liprina1. However, we believe that the regulation of liprina1
levels by CaMKII occurs substantially in the postsynaptic
compartment because RNAi knockdown of CaMKII in
neurons resulted in increased immunostaining of dendritic
liprina1 in a cell-autonomous fashion (Figure S2). Regula-
tion of liprina1 by APC must also occur at least in part on
the postsynaptic side, because Cdh1 RNAi boosted
liprina1 signal in dendrites of transfected neurons. Finally,
CaMKII-insensitive liprina1 caused robust changes in
dendrite morphology in transfected neurons, implying
that this mutant can have a postsynaptic (or dendritic) lo-
cus of action. Nevertheless, our study does not rule out an
effect of CaMKII or APC on liprina1 in presynaptic com-
partments.Figure 5. Impairment of Dendrite Morphogenesis by Liprina1 Mutants Insensitive to CaMKII Degradation, LAR-Liprin Interfering
Constructs, and LAR-shRNA
(A) Morphology of hippocampal neurons (visualized in the RFP channel) cotransfected at DIV13 for 4 days with control vector, GFP-liprina1, or GFP-
liprina1DPESTDC, plus mRFP as transfection marker. ‘‘+ KN93’’ indicates treatment for 24 hr with 10 mMKN93 to inhibit CaMKII. GFP-liprina1 signals
are shown in insets.
(B) Representative images (RFP channel) of hippocampal neurons cotransfected at DIV13 for 4 days with control vector, LAR-liprin interfering con-
structs, or LAR-shRNA, plus mRFP to visualize the transfected cell. The scale bar represents 20 mm.
(C) Sholl analysis of hippocampal neurons transfected at DIV13 for 4 days with liprina1, LAR, and shRNA constructs.
(D–F) Quantification of total dendritic length (D), number of dendritic tips (E), and number of primary dendrites (F) in hippocampal neurons transfected
at DIV13 for 4 days with indicated constructs (mean ± SEM). *p < 0.05, **p < 0.005, ***p < 0.0005.lopmental Cell 12, 587–602, April 2007 ª2007 Elsevier Inc. 597
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Expression in HeLa Cells
(A–D) HeLa cells were double-transfectedwith CD8-LARCplus HA-liprina1 (A), HA-liprina1DPESTDC (B), HA-liprina1DCM (C), or with CD8-LARCDD2
plus HA-liprina1DPESTDC (D), and then fixed and stained with anti-HA (red) and anti-CD8 (green) antibodies. The merge is shown in color at right.598 Developmental Cell 12, 587–602, April 2007 ª2007 Elsevier Inc.
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for Dendrite Morphogenesis
CaMKII has been implicated in neuronal morphogenesis
and synapse maturation (Lisman et al., 2002; Wong and
Ghosh, 2002). CaMKII signaling can regulate dendrite de-
velopment by local processes or by inducing transcrip-
tional programs in the nucleus (Gaudilliere et al., 2004).
CaMKII activity promotes growth and stabilization of den-
drites in Xenopus optic tectal neurons (Wu and Cline,
1998) and of dendritic spines in hippocampal neurons
(Fink et al., 2003). The precise mechanisms by which
CaMKII influences dendrite and synapse development re-
main poorly understood. Based on our findings, we pro-
pose that CaMKII-mediated phosphorylation and deg-
radation of liprina1 is one molecular mechanism for
coupling activity to dendrite and synapse morphogenesis.
Liprina1 mutants resistant to CaMKII degradation impair
dendrite arborization and synapse density; thus, the ability
of liprina1 protein to be degraded in response to CaMKII
activation is essential for normal dendrite and synapse de-
velopment. Because CaMKII can be stimulated locally by
synaptic activity, suppression of liprina1 by CaMKII might
be used to promote dendrite growth or stability locally in
regions of high synaptic activity. Our data correlate well
with previous studies showing that activity—specifically
stimulation of glutamate receptors in mature neurons—
stabilizes dendritic arbors (Cline, 2001), and that inhibition
of CaMKII with RNAi or peptide inhibitors reduces den-
dritic arborization and synapse formation (Fink et al.,
2003).
How does liprina1 regulate dendrite morphology? Two
obvious candidates are the known liprina1 binding pro-
teins GRIP1 (Wyszynski et al., 2002) and LAR-RPTP
(Serra-Pages et al., 1998, 2005). GRIP1 has already
been implicated in dendrite development (Hoogenraad
et al., 2005); however, CaMKII-nondegradable mutants
of liprina1 had no effect on the distribution of GRIP1 in hip-
pocampal neurons (data not shown). Here we show that
RNAi knockdown of LAR and disruption of the LAR-liprina
interaction reduce dendritic arbor complexity in cultured
hippocampal neurons very similarly to that seen with
CaMKII-nondegradable liprina1 mutants. Previous work
has suggested that liprina is involved in the localization
and distribution of LAR in mammalian cells (Serra-Pages
et al., 1995, 1998). Our experiments indicate that liprina1
drives LAR receptors out of the Golgi and enhances LAR
expression and clustering on the neuronal cell body, likely
associated with an increased surface expression. This
function was independent of liprina1 degradation by
CaMKII in thatDPESTDCandDPEST/S-Amutants of liprina1
were fully active in this respect. However, specifically
the targeting of LAR to dendrites was abrogated by
liprina1 mutants that are immune to CaMKII degradation,
as well as by KN93 block of CaMKII activity, even thoughDeveloboth manipulations greatly increase liprina1 levels in neu-
rons. Because postsynaptic LAR is critical for dendrite de-
velopment and synapse/spine maturation (this study; Du-
nah et al., 2005), the loss of dendritic targeting of LAR can
largely explain the phenotype of CaMKII-nondegradable
liprina1 overexpression.
So why is the degradation of liprina1, rather than just its
expression, important for LAR distribution and dendrite
and synapse development? Although we can only manip-
ulate CaMKII activity or liprina1 expression at a global
level within individual neurons, the physiological role of
CaMKII regulation of liprina-LAR occurs most likely at
the local level. We hypothesize that the local regulation
of liprina1 levels by CaMKII controls the trafficking of
LAR to specific regions within dendrites and/or to specific
synapses. The CaMKII-mediated degradation of liprina1
provides an attractive mechanism for targeting liprina1-
LAR complexes to active synapses where the kinase is
switched ‘‘on.’’ We suggest that at such sites, the LAR
cargo bound to liprina1would be ‘‘unloaded’’ due to CaM-
KII-mediated degradation of liprina1 to promote local
growth and stabilization of dendritic structures. However,
it is possible that themutations that blockCaMKII-mediated
degradation interfere in some other way with liprina1’s
trafficking function in dendrites.
In yeast, a specific myosin motor, Myo2p, moves vacu-
oles to the yeast bud by binding to the vacuole-specific
Myo2p receptor Vac17p (Tang et al., 2003). The transport
complex is disrupted specifically in the bud by degrada-
tion of Vac17p, depositing the vacuole in the bud.
Vac17p contains a PEST sequence that is required for
its degradation, and loss of this PEST sequence causes
mistargeting of vacuoles (Tang et al., 2003). By analogy
to Vac17p, liprina1 also interacts with motor proteins
(kinesin-1 and kinesin-3; KIF1A) (Miller et al., 2005; Shin
et al., 2003). Liprina1 also contains a PEST sequence im-
portant for rapid degradation, and causes a cargo target-
ing phenotype when it is rendered nondegradable. An at-
tractive idea is that PEST protein degradation in yeast and
hippocampal neurons represent different aspects of
a general molecular mechanism for directed motor traf-
ficking.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents
Rabbit liprin (1069) antibody was previously described (Dunah et al.,
2005; Wyszynski et al., 2002). Details of other antibodies and reagents
are available in the Supplemental Data.
DNA Constructs
The following mammalian expression plasmids have been described:
myc-liprina1, myc-liprina2, HA-liprinb1 (Wyszynski et al., 2002),
pSuper-Cdh1-shRNA (Konishi et al., 2004), pSuper-LAR-shRNA, and
myr-HA-LAR-D2 (Dunah et al., 2005). CD8-LARC and CD8-LARCDD2Arrowheads indicate CD8-LARC localization in the perinuclear Golgi region (A, C, and D). Coexpression of liprina1 (A) or liprina1mutants insensitive to
CaMKII degradation (B) enhance surface expression of CD8-LARC. The scale bars represent 10 mm.
(E and F) HeLa cells transfected with CD8-LARC and control GFP (E) or GFP-liprina1DPESTDC (F) and immunostained for surface CD8 expression
under nonpermeabilizing conditions. Liprina1 mutants insensitive to CaMKII degradation enhance surface expression of CD8-LARC.pmental Cell 12, 587–602, April 2007 ª2007 Elsevier Inc. 599
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and without the D2 domain of human LAR in frame with the extracellu-
lar and transmembrane domain of CD8 (Hoogenraad et al., 2005).
CaMKII-shRNA sequences were targeted against rat CaMKIIa mRNA
(GenBank accession number NM_012920) and rat CaMKIIb mRNA
(GenBank accession number NM_021739) corresponding to nucleo-
tides 77–95 (CaMKIIa-shRNA) and 173–191 (CaMKIIb-shRNA), re-
spectively. APC2-shRNA sequences were targeted against rat APC2
(GenBank accession number BC107471; APC2-shRNA1: nucleotides
1554–1572 and APC2-shRNA2: nucleotides 1482–1500). For details
of other constructs, see the Supplemental Data.
Primary Hippocampal Neuron Cultures, Transfection,
and Immunocytochemistry
Primary hippocampal cultures were prepared from embryonic day 18
(E18) rat brains and transfectedwith various DNA constructs using Lip-
ofectamine 2000 (Invitrogen) as described in the Supplemental Data.
For immunocytochemistry, neurons were fixed for 10 min with 4%
formaldehyde/4% sucrose in phosphate-buffered saline (PBS) at
room temperature or ice-cold 100% methanol at 20C, washed
two times for 30 min with PBS at room temperature, and incubated
with primary antibodies in GDB buffer (0.2% BSA, 0.8 M NaCl, 0.5%
Triton X-100, 30 mM phosphate buffer [pH 7.4]) overnight at 4C. De-
tails of immunocytochemistry, image analysis, and quantification as
well as immunoprecipitation and immunoblotting are available in the
Supplemental Data.
Supplemental Data
Supplemental Data include seven figures and Supplemental
Experimental Procedures and are available at http://www.
developmentalcell.com/cgi/content/full/12/4/587/DC1/.
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